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ABSTRACT 
Objective: Patients with atherosclerotic cardiovascular disease (CVD) vary significantly in their risk of 
future CVD events yet few clinical scores are available to aid assessment of risk. We sought to 
develop a score for use in primary care that estimates short-term CVD risk in these patients.   
Methods: Adults aged <80 years with prior CVD were identified from a New Zealand primary care 
cohort study (PREDICT), and linked to national mortality, hospitalisation, and dispensing databases. A 
Cox model with an outcome of myocardial infarction, stroke or CVD death within 2 years was 
developed. External validation was performed in a cohort from the United Kingdom (UK).   
Results: 24,927 patients, 63% men, 63% European, median age 65 years (IQR 58-72 years), 
experienced 1,480 CVD events within 2 years after a CVD risk assessment. A risk score including 
ethnicity, co-morbidities, BMI, creatinine, and treatment, in addition to established risk factors used 
in primary prevention, predicted a median 2-year CVD risk of 5.0% (IQR 3.5-8.3%).  A plot of actual 
against predicted event rates showed very good calibration throughout the risk range.  The score 
performed well in the UK cohort but overestimated risk for those at highest risk, who were 
predominantly patients defined as having heart failure.   
Conclusions: The PREDICT-CVD secondary prevention score uses routine measurements from clinical 
practice that enable it to be implemented in a primary care setting. The score will facilitate risk 
communication between primary care practitioners and patients with prior CVD, particularly as a 
resource to show the benefit of risk factor modification.  
Keywords:  cardiovascular disease; risk score; secondary prevention; electronic health record 
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KEY QUESTIONS 
 
What is already known about this subject? 
Patients with established cardiovascular disease (CVD) are largely managed in primary care and, in 
contrast to patients without CVD, there is minimal guidance to the clinician or patient about 
stratifying risk and thus the benefit of risk factor modification.  
 
What does this study add? 
The PREDICT-CVD secondary prevention score shows that not all patients with CVD are at uniformly 
high risk of experiencing a subsequent CVD event. In addition to established risk factors for primary 
prevention, the score includes ethnicity, heart failure, the severity of the prior CVD event (MI or 
stroke), BMI, creatinine, and lipid and blood pressure lowering treatment.  The full equation and an 
example of how it is calculated is included in this manuscript. 
 
How might this impact on clinical practice? 
The new score  may help in communication with patients with existing CVD, to recognise patient-
specific risks of future events and how they may be reduced through therapeutic and behavioural 
strategies. In combination with primary prevention scores, the new score will enable quantitative 
stratification of risk across the continuum of primary and secondary CVD prevention in primary care.  
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INTRODUCTION 
Cardiovascular disease (CVD) risk prediction scores are available for use at the time of an acute CVD 
event.1, 2 However patients are living longer with established CVD and few scores are available that 
estimate an individual patient’s CVD risk at a time distant to an acute event.3  International clinical 
guidelines4-6 recommend that patients without prior CVD have their CVD risk estimated by risk 
scores6-10 and that the intensity of risk factor management should be informed by the predicted 
absolute CVD risk.11  In contrast, patients with established CVD are usually considered at “clinically 
high risk” without any further risk stratification.4-6 Patients find this message demotivating12 and 
primary care practitioners have little to no resource to show the benefit of risk factor modification. 
Nearly half of CVD events occur in patients with prior CVD13 and there is evidence of important risk 
heterogeneity within this group.13,3  A score to stratify risk in those with known CVD in the primary 
care setting would complement the established approach of CVD risk assessment for those without 
CVD, and contribute to a suite of risk scores that are relevant to an individual at any point in their 
continuum of CVD risk.   
 
The New Zealand (NZ) PREDICT CVD Cohort Study was initiated in 2002 to develop CVD risk scores for 
a range of populations.  PREDICT decision support software includes currently recommended CVD 
risk scores and is integrated with the electronic patient management systems of over one-third of NZ 
primary care practitioners. Relevant data from the electronic health record are automatically 
extracted and additional data are entered during the patient’s clinical assessment. Thus the study 
infrastructure not only collects routine measurements taken directly from clinical practice, but 
provides a mechanism by which new risk scores can be developed and implemented back into clinical 
practice.  
 
We sought to develop and validate a CVD risk score for use in primary care that estimates 2-year 
fatal and non-fatal CVD risk in patients with established CVD.  Score development was supported by 
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anonymised linkage of the PREDICT data to national and regional administrative health datasets. 
Collaboration with CALIBER investigators enabled a validation cohort from the United Kingdom (UK) 
to be developed, and for factors affecting the transferability of the score into clinical practice to be 
identified.
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METHODS 
Patient cohort 
The PREDICT web-based decision support programme has been described previously.14  When 
PREDICT is used by a practitioner to estimate CVD risk for a patient, an electronic risk profile is stored 
both in the patient record and anonymously in a central database.  With the permission of health 
providers, this profile is linked to an encrypted National Health Index number (eNHI) and made 
available to researchers at the University of Auckland.  At the time of these analyses 272,682 people 
with and without CVD were enrolled in PREDICT. 
 
A derivation cohort was created that included NZ residents aged 18-80 years who received a PREDICT 
assessment in primary care between January 2006 and April 2012, and where the clinician (GP) had 
recorded prior CVD as at least one of:  angina, myocardial infarction (MI), percutaneous coronary 
intervention (PCI) or coronary artery bypass grafts (CABG), transient ischaemic attack (TIA), ischaemic 
stroke, or peripheral vascular disease (PVD).  The first PREDICT assessment at which a history of CVD 
was recorded is the index assessment. 
 
Data considerations 
Clinical data from this subset of PREDICT patients were anonymously linked to national hospital 
discharge and mortality data, pharmaceutical dispensing, and regional laboratory tests via the unique 
eNHI.  Pharmaceutical data were limited to cardiovascular medications dispensed within six months 
prior to the index assessment.  Laboratory data were limited to the most recent values of blood 
cholesterol fractions recorded up to one year prior or two weeks after the index assessment, or up to 
five years prior for blood creatinine. A five year timeframe for creatinine was considered realistic 
among clinically stable out-patients, and preliminary analyses showed 90% of values were measured 
within 2 years. Thus the study dataset includes clinical and demographic information recorded at the 
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time of the index assessment, the most recent dispensing and laboratory information, and 
subsequent hospitalisations and deaths. The end of follow-up was 30 April 2012. 
 
A clinician-defined diagnosis of heart failure (HF) was not available in the PREDICT database.  Thus 
the presence of HF was defined as an ICD-coded hospitalisation for HF at any prior date and/or 
dispensing of a loop diuretic during the 6 months prior to the index risk assessment.  This definition 
therefore represents a spectrum of HF, including patients who have not been hospitalised.  In NZ it is 
unusual for loop diuretics to be used for indications other than HF. Forty percent of patients with HF 
as defined met both criteria, 30% were based on prior hospitalisation only, and 31% by loop diuretic 
use only.  Sensitivity analyses showed that the 2-year event rate among patients receiving a loop 
diuretic was 14%, compared to 18% among patients with a prior HF hospitalisation. 
 
Blood pressure (BP) lowering medication is defined as at least one dispensing of a: beta-blocker, 
angiotensin-converting enzyme inhibitor (ACEi), angiotensin receptor blocker, calcium channel 
blocker, or other anti-hypertensive agent in the 6 months prior to the index risk assessment.  
Anticoagulation is defined as dispensing of warfarin only, as novel oral anticoagulants were not used 
in NZ during the period of data collection, and low molecular weight heparin is not part of standard 
general practice in NZ.  
 
The outcome of interest was time to first new CVD event within 2 years of the index risk assessment.  
A CVD event was defined as MI, ischaemic or haemorrhagic stroke, or CVD death, defined from ICD-
10-AM coded national hospital and mortality datasets.  Patients having a non-CVD death were 
censored at the date of death. 
 
Statistical approach 
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Potential predictors were selected a priori based on clinical relevance from those routinely measured 
in practice.  They were: age, sex, ethnicity, family history of premature CVD, diabetes, smoking, prior 
MI or stroke, HF, body mass index (BMI), systolic BP (SBP), ratio of total to high-density lipoprotein 
cholesterol (TC:HDL), creatinine, dispensing of a BP lowering medication or a statin.  Interactions 
between SBP and BP lowering medications, TC:HDL and statins, and ethnicity and diabetes, were 
assessed. Ethnicity was defined according to a national prioritisation protocol in the order: Māori, 
Pacific, Indian, East Asian (Chinese and other non-Indian Asian), European/other. Over 98% of the 
latter group were classified as European.  
 
Data on BMI and two laboratory variables were missing for 20% patients (BMI), 22% patients 
(creatinine up to 5 years prior), and 26% patients (TC:HDL up to 1 year prior). Therefore multiple 
imputation using chained equations was performed.15  The imputation process is described in 
Appendix D.   
 
The 2-year event rate was modelled using multivariable Cox regression.  Validity of the proportional 
hazards assumption was confirmed from visual inspection of Schoenfeld residual plots, and linearity 
of the relationship between each predictor and the log hazard were assessed via plots of Martingale 
residuals.16, 17  Where non-linear relationships affected more than 5% of patients, variables were 
categorised at clinically relevant thresholds (age, creatinine).  BMI and SBP were categorised at pre-
determined thresholds to assess known U-shaped relationships between these measures and 
outcome.18, 19 Alternative approaches to non-linearity were possible, but as the aim was to produce 
risk scores to be used in clinical practice, categorisation into clinically relevant groups was the 
preferred approach.   
 
Risk score 
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Multivariable risk from the Cox model was transformed to absolute risk by estimating the baseline 
hazard at the mean values of continuous covariates and the reference group of categorical 
covariates. The prognostic index, or sum of each coefficient multiplied by the measured variable, was 
centred on the mean prognostic index.20  Risk was calculated for each imputed dataset and the 
average obtained. 
 
Performance 
Model calibration is represented by plots of the observed event rate (from Kaplan-Meier estimates) 
against predicted event rate within deciles of predicted risk. Global model fit was assessed with the 
Cox & Snell R2 and Nagelkerke’s R2. 21,22  Model discrimination was quantified by Harrell’s c-statistic23 
and the Gӧnen & Heller K-statistic24, and represented visually by plotting the proportion of events 
against deciles of the cohort after patients were ranked by increasing predicted risk. The model fit 
and discrimination statistics are the median and interquartile range (IQR) of each statistic derived 
from the 25 imputation models. 
 
Validation 
External validation was performed by applying the risk scores to a cohort of patients with established 
CVD in the UK (January 2005-December 2010).  In collaboration with the CALIBER research group25, 
and with approval from the relevant governance groups, anonymised data from linked primary care 
and national datasets were accessed through an ISO27001 certified data safe-haven provided by 
University College London.  The definition of CVD matched that used to develop the NZ scores. 
Appendix D presents a comparison of the derivation and validation cohorts. 
 
Analyses were performed using R v3.0.226, including the ‘survival’, ‘Hmisc’, and ‘mice’ packages.  The 
cohort study and research process was approved by the NZ Northern Region Ethics Committee Y 
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(AKY/03/12/314) with subsequent annual approval by the National Multi-Region Ethics Committee 
(MEC/07/19/EXP). 
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RESULTS 
Data on 30,343 adults with established CVD were recorded in the PREDICT database between 
January 2006 and April 2012.  After limiting to NZ residents aged <80 years, the remaining 24,927 
patients form the derivation cohort (Appendix A Table S1).   
 
Almost two-thirds of the cohort were men and median age was 65 years (IQR 58-72 years).  The 
study population were 17% NZ Māori, 10% Pacific, 6% Indian and 4% East Asian, with the remaining 
two-thirds were European.  One-third had diabetes, one-third had a BMI >30 kg/m2, and one fifth 
had HF.  Over 80% were receiving a BP lowering medication, 75% a statin, and 9% were on warfarin.  
A total of 2,240 CVD events occurred, of which 1,480 occurred within 2 years (5.9% mean 2-year 
event rate). Half of these events occurred within the 20% of the cohort identified as having HF.   
 
For two thirds of the cohort, their prior CVD event was a coded hospital admission.  The median time 
between the most recent hospitalisation and risk assessment in primary care was 1.2 years indicating 
a cohort with stable CVD (Appendix A Table S2). Dates of previous hospitalisations are not 
consistently available to GPs at the time of patient assessment so have not been included in the 
current score. 
 
Multivariable model 
The risk of a CVD event within 2 years increased with increasing age, particularly after age 60 (Table 
1).  Compared to European participants, Pacific and Māori were at higher risk and East Asians were at 
lower risk. Risk increased if the prior event was an MI or stroke hospitalisation, and was significantly 
higher among people with heart failure, diabetes, or current smokers.  Being underweight was 
associated with significantly greater risk than those of normal BMI however risk progressively 
decreased as BMI increased above 30 kg/m2. A U-shaped relationship between SBP and outcome was 
seen, with increased risk when SBP <100 mmHg or ≥160 mmHg. Risk increased with increasing 
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TC:HDL and creatinine.  Interactions between SBP and BP lowering medications, TC:HDL and statins, 
and ethnicity and diabetes, were not statistically significant.  
 
 
Absolute risk 
Using the baseline survival estimate in Table 1, median absolute 2-year risk of a CV event was 5.0% 
(IQR 3.5-8.3%).  Event rate stratified by tertiles of predicted risk is shown in Figure 1. The risk 
equation is provided in Appendix B. 
 
Model performance 
Eighty percent of the cohort had an estimated 2-year risk of <10% and Figure 2a shows very good 
calibration throughout this range of risk. The model slightly under-predicts risk in the 9th decile of risk 
(10-18%) however is well calibrated in those at highest risk (>18%).  Nagelkerke’s R2 was 5.8% (IQR 
5.78, 5.83%), Harrell’s c-statistic 0.7236 (IQR 0.723, 0.724), and Gӧnen & Heller’s K-statistic 0.6727 
(IQR 0.672-0.673) (Appendix C).  Discrimination of the score was also assessed visually after ranking 
the cohort by increasing estimated risk and dividing into deciles (2493 people per decile with 2490 in 
decile 10; Figure 3). Over half of the events (52%, n=772) occurred in the 20% of the cohort identified 
as being at highest risk, showing good discrimination.    
 
External validation was performed by applying the NZ equation to the UK dataset of 32,756 patients 
(Appendix E).  Among the UK cohort, 1517 (4.7%) CVD events occurred within 2 years and median 
estimated risk was 5.2% (IQR 3.7-8.2%). The calibration plot showed the NZ equation generally 
overestimated risk in the UK cohort. Overestimation was minor for the 60% of the cohort with an 
event rate of <5%, increased slightly for the 20% of the cohort with an event rate of 5-7%, then 
clearly overestimated risk in the highest 20% of the cohort (Figure 2b).  
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DISCUSSION 
We present a new algorithm to improve CVD risk stratification in primary care for patients with 
established CVD. This is the first contemporary score that enables quantitative risk estimation for all 
patients with CVD, at a time distant to their CVD event.  The risk of a future CVD event varied widely, 
with the median 2-year risk of CV death, MI or stroke ranging from 2% in the lowest risk decile to 
34% in the highest risk decile. Over half of all CVD events occurred in the twenty percent of the 
cohort with the highest risk. When combined with primary prevention scores, this new score will 
enable quantitative stratification of risk across the continuum of primary and secondary CVD 
prevention.  
 
External validation was performed by applying the score to a cohort of patients in a different 
country, allowing us to assess its geographic transportability.27  The median risks estimated for UK 
and NZ patients were very similar (UK 5.2%, NZ 5.0%) although the NZ score tended to overestimate 
risk in the UK cohort.  Compared to the NZ cohort, the UK cohort had a very different ethnic profile 
(no Māori or Pacific Islander ), lower rates of prior MI or stroke (25% vs 47%) and diabetes (29% vs 
36%), and greater BP lowering (91% vs 82%) and statin use (87% vs 75%) (Appendix D).  Risk 
overestimation was greatest among the 20% of patients at highest risk, which are almost entirely 
those with HF.  Heart failure was defined in the same way in both datasets however the event rate in 
this group of patients was significantly lower in the UK than in NZ (8.5% vs 14.6%).  The majority 
(70%) of HF patients in the NZ cohort were defined via a prior hospitalisation for HF. In comparison, 
only 31% of patients with HF in the UK cohort had a prior hospitalisation for HF.  Thus differences in 
clinical practice between the two countries, such as the use of loop diuretics and coding of HF, may 
have contributed to the difference in score performance. Further analysis, including characterising 
the patients in whom the scores did not predict risk well, is beyond the scope of the current paper 
and will be explored in subsequent work.  
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Within secondary prevention models, a number of factors have been consistently important in their 
association with a subsequent event.  In a Framingham model28, TC:HDL and diabetes were 
significant predictors, with SBP and smoking also significant among women.  The REACH registry29 of 
>45,000 patients with CVD from 29 countries was the basis of a model with similar eligibility and 
outcome definitions to our study, and similarly found HF, diabetes, smoking, a prior ischaemic event, 
and BMI<20 kg/m2 to be statistically significant.  Models from patients with CAD 3, 30, 31 also found 
similar significant factors, although HF was not significant in the EUROPA trial when predicting CV 
death, MI or cardiac arrest. The CALIBER group included 31 variables in models for stable CAD 
patients to estimate risk of all-cause mortality and of non-fatal MI or coronary death.3 In contrast to 
other studies, we did not see a gender difference in risk and instead suggest a levelling effect once 
CVD has been established.  This may be influenced by the greater representation of men in other 
cohorts, comprising up to 85% of subjects in clinical trials.   
 
Clinical implications 
The risk estimate guides clinicians and patients in their discussions of individualised care planning. 
Instead of patients with prior CVD simply being told they are at “clinically high risk”, risk stratification 
informs more individualised care, and aids a discussion of factors amenable to risk reduction with 
lifestyle and medication changes.  Most of the patients in this cohort were already on secondary 
prevention therapy and the observed risk is therefore an on-treatment risk, although this does not 
imply optimal dosage or therapy combination.  High risk can be mitigated by ensuring patients are 
not only receiving standard secondary prevention therapies, but that dosages of medications are 
optimised for the individual, other risk factors (such as smoking) are readdressed, and management 
of coexisting conditions such as diabetes are optimised. The score will also facilitate risk 
communication, aiding the healthcare professional/patient interaction and thus optimising 
implementation of risk reduction therapies. Clinical trials stratifying patients on the basis of risk are 
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needed to quantify the benefit of additional therapies. A relatively low risk should not be used as a 
justification for not intensifying management or for withdrawing treatment. 
 
Limitations 
Additional variables that may inform CVD risk, such as NT-proBNP, hsCRP and cognitive status, are 
not routinely measured in all patients and so are not available for inclusion in risk model 
development using general practice records and administrative data.  Similarly, an index of 
socioeconomic disadvantage was included in preliminary analyses, in which increasing deprivation 
was associated with a modest increase in risk (adjusted HR = 1.07 per quintile of deprivation score). 
However as socioeconomic indices are country-specific, and may not be routinely available in 
primary care, we elected to remove this variable from the risk score. 
 
The risk horizon of 2 years is shorter than the more familiar 5 or 10 years associated with primary 
prevention scores, which is important to bear in mind to avoid underestimation of risk in this patient 
group. Future risk scores will include extending the risk horizon to 5 years (when there is sufficient 
duration of follow up for such models to be developed).    
 
It is difficult to identify an appropriate population for external validation. The NZ data used to 
develop the risk scores came from an explicit standardised CVD risk assessment undertaken in 
primary care and augmented by national dispensing and regional laboratory data.  In contrast, the UK 
data used for validation were from incidental primary care visits not necessarily related to a CVD risk 
assessment. Completeness and timing of the measurements were therefore variable and, as 
discussed above, the NZ and UK cohorts have different risk profiles and event rates, particularly 
among HF patients.  
 
Conclusions 
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A new score has been developed to improve CVD risk stratification for patients with prior CVD in the 
community. The score can identify the highest risk patients who may benefit from more intensive 
risk management, and when made available alongside models for predicting risk in those without 
prior CVD, will enable risk stratification over the life-course of cardiovascular risk and disease. 
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Figure legend 
 
Figure 1 Event rate stratified by tertiles of predicted risk 
 The absolute risk bounds for each tertile are: 1.0-3.7%, 3.7-6.9%, 6.9-75.7%. Dashed 
lines represent the 95% confidence interval. 
 
Figure 2 Model calibration in the development and external validation cohorts 
Calibration of the risk equation in a) the development cohort (New Zealand), and b) 
the external cohort (United Kingdom). For both plots, calibration is shown as the 
actual survival from Kaplan-Meier analysis against estimated risk (in deciles).  Dashed 
line = perfect calibration. 
 
Figure 3 Discrimination plot showing the percentage of events that occurred per decile of 
the development cohort, ranked by estimated risk.  
The absolute risk bounds for each decile are: 1.0-2.6%, 2.6-3.2%, 3.2-3.8%, 3.8-4.3%, 
4.3-5.0%, 5.0-5.9%, 5.9-7.3%, 7.3-10.1%, 10.1-16.0%, 16.0-75.7%. 
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Table 1  Multivariable models of time to subsequent cardiovascular event within 2 years 
 
Variable Levels Adjusted Hazard Ratio (95% confidence interval) 
Patient factors   
Male  1.04 (0.93, 1.16) 
Age, years 50-59 1.05 (0.83, 1.34) 
 60-69 1.27 (1.01, 1.61) 
 70-79 1.69 (1.33, 2.15) 
Ethnicity NZ Māori 1.26 (1.10, 1.45) 
 Pacific 1.51 (1.29, 1.77) 
 Indian 1.18 (0.95, 1.48) 
 East Asian 0.60 (0.40, 0.90) 
Medical history  
Prior MI or stroke 1.52 (1.37-1.69) 
Heart failure 2.85 (2.53-3.22) 
Diabetes  1.36 (1.22, 1.53) 
Current smoker 1.27 (1.10-1.47) 
Clinical factors   
Body mass index, kg/m2 <18.5 2.26 (1.32, 3.88) 
 18.5-25 1.10 (0.92, 1.30) 
 30-35 0.85 (0.73, 0.99) 
 35-40 0.77 (0.63, 0.93) 
 ≥40 0.68 (0.53, 0.86) 
Systolic BP, mmHg <100 1.57 (1.08, 2.28) 
 120-140 0.99 (0.85, 1.14) 
 140-160 1.10 (0.94, 1.30) 
 ≥160 1.39 (1.12, 1.74) 
Laboratory values   
Total:HDL cholesterol  1.11 (1.07, 1.17) 
Creatinine, µmol/L 100-150 1.34 (1.17, 1.53) 
 ≥150 1.96 (1.63, 2.36) 
Medications   
BP lowering  1.14 (0.96, 1.36) 
Statin  1.10 (0.96, 1.25) 
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Baseline survival  0.94235 
 
NZ=New Zealand, BP=blood pressure, MI=myocardial infarction, HDL=high-density lipoprotein. 
 
Referent for: sex=women; age=18-49 years; ethnicity=European/other; BMI=25-30 kg/m2; systolic 
BP=100-120 mmHg; creatinine=<100 umol/L.   
 
Values in bold represent statistical significance (p<0.05). 
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Figure 1 Event rate stratified by tertiles of predicted risk 
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Figure 2 Model calibration in the development and external validation cohorts  
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Figure 3 Discrimination plot comparing the proportion of the cohort, ranked from lowest to 
highest predicted risk , to the percentage of events that actually occurred in that proportion of the 
cohort 
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APPENDIX A DERIVATION COHORT 
Table S1 Participant characteristics, n=24,927 
Men 15,814 (63)  
Age, years 65 (58, 72)  
  ≥ 70 years 8,201 (33)  
European/other* 15,665 (63)  
NZ Māori 4,197 (17)  
Pacific 2,592 (10)  
Indian 1,503 (6)  
East Asian 970 (4)  
Family history of premature CVD 5,141 (21)  
Medical history   
Prior MI or stroke 11,695 (47)  
Heart failure 5,100 (20)  
Diabetes 8,930 (36)  
Current smoker 3,678 (15)  
Clinical measurements   
Body mass index (BMI), kg/m2 29 (26, 33)  
   BMI < 18.5 kg/m2 163 (0.7)  
   BMI ≥30 kg/m2 10,992 (44)  
Systolic BP (SBP), mmHg 130 (121, 141)  
   SBP < 100 mmHg 253 (1.0)  
   SBP ≥160 mmHg  1,383 (5.5)  
TC:HDL 3.6 (3.0, 4.4)  
Creatinine, μmol/L 85 (73, 99)  
Medications   
BP lowering 20,513 (82)  
Statin 18,739 (75)  
Anticoagulation 2,339 (9)  
Follow-up   
Total follow-up, years 2.0 (0.9, 3.3)  
CV deaths 764 (3.1)  
CV events 2,240 (9.0)  
29 
 
By 2 years    
CV deaths 423 (1.7)  
CV events 1,480 (5.9)  
Values are n (%) or median (inter-quartile range).  *<2% were “other” 
NZ=New Zealand, BP=blood pressure, MI=myocardial infarction, TC:HDL=ratio of total to high-density 
lipoprotein, CV=cardiovascular, CV event = MI, ischaemic or haemorrhagic stroke, or CV death 
 
 
 
Table S2 Time between hospitalisation and index risk assessment in primary care 
Timeframe Number of 
patients 
% 
< 30 days 1277 7.8 
30 days – 6 months 3584 22.0 
6 months – 12 months 2677 16.4 
12 – 18 months 1706 10.5 
18-24 months 1244 7.6 
≥ 24 months 5795 35.6 
TOTAL 16283  
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APPENDIX B RISK SCORE 
 
  EXAMPLE 
 Coefficient Patient A Variable * coefficient  
Male 0.03587575 Female 0 
Age 50-59 years 0. 05342182  0 
Age 60-69 years 0. 24286832 63 years old 0.24286832 
Age 70-79 years 0.52462088  0 
East Asian - 0.50879097  0 
Indian 0.16911057 Indian 0.16911057 
Māori 0.23015796  0 
Pacific 0.41315010  0 
Diabetes 0.31073697 Diabetes 0.31073697 
Current smoker 0.23873539 Non-smoker 0 
Prior MI or stroke 0.42372976 Prior MI 0.42372976 
Heart failure 1.07493660 With heart failure 1.07493660 
BMI < 18.5 0.81581102  0 
BMI 18.5-25 0.09252985  0 
BMI 30-35 - 0.16091766  0 
BMI 35-40 - 0.26400754 BMI = 36 kg/m2 -0.26400754 
BMI ≥ 40 - 0.38904755  0 
SBP < 100 0.44988432  0 
SBP 120-140 - 0.01460494  0 
SBP 140-160 0.09897459 SBP = 142 mmHg 0.09897459 
SBP ≥160 0.33063441  0 
TC:HDL, per unit 0.10795178 TC:HDL = 4.2 0.4533975 
Creatinine 100-150 0.29119313 Creatinine = 80 µmol/L 0 
Creatinine≥150 0.67363029  0 
Statin 0.09119116 Taking a statin 0.09119116 
BP lowering 0.13462192 Taking ACEi & b-blocker 0.13462192 
  PI = Sum = 2.73556 
Mean PI 1.577184   
Baseline survival 0.94235   
    
PI = prognostic index 
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PREDICT secondary prevention risk score 
2-year risk of CVD event = 1 – Baseline survivalexp(PI – mean PI) 
    = 1 - 0.94235exp(PI – 1.577184) 
 
Thus Patient A’s 2-year risk of a subsequent CVD event 
 = 1 - 0.94235 exp( 2.73556 – 1.577184 ) 
 =  0.1723014 
 = 17.2% 
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APPENDIX C MODEL PERFORMANCE   
 Performance metrics 
Apparent performance*  
Model fit Cox & Snell R2, % 4.00 (3.98, 4.02) 
 Nagelkerke R2, % 5.81 (5.78, 5.83) 
Discrimination Harrell c-statistic  0.7236 (0.7228, 0.7244) 
 Gönen & Heller  0.6727 (0.6725, 0.6734) 
Calibration Observed v expected plots  
  
Internal validation**  
Model fit Cox & Snell R2, % 4.09 (4.07, 4.12) 
 Nagelkerke R2, % 5.95 (5.90, 5.98) 
Discrimination Harrell c-statistic 0.7258 (0.7249, 0.7264) 
 Gönen & Heller 0.6754 (0.6749, 0.6759) 
External validation  
Calibration Observed v expected plots  
   
*Values are median (IQR) from 25 imputation models; **Values are median (IQR) from all bootstrap 
and imputation 
 
 
 
 
APPENDIX D MULTIPLE IMPUTATION OF THE DERIVATION (PREDICT) DATA 
 
In the PREDICT cohort, the proportion missing from each variable were: BMI 20%, TC:HDL 26%, 
creatinine 22%.  It was reasonable to assume that data were missing at random therefore multiple 
imputation using chained equations was performed.  
 
All predictors in the risk model were in the imputation model, as well as glucose, urate, WCC, and Hb.  
The event indicator and the Nelson-Aalen estimator were also included.  There were variable 
patterns of missingness among patients with and without diabetes thus imputation was performed 
separately in those with and without diabetes then combined for each iteration of the substantive 
model.   For each of 25 imputations, 10 random draws from the distribution defined by the 
imputation equations were made for each of the variables with missing data.  
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APPENDIX E EXTERNAL VALIDATION 
 
Table S3      Comparison of participant characteristics in derivation and external validation cohorts 
 New Zealand 
(PREDICT) 
United Kingdom 
(CALIBER)* 
United Kingdom 
(CALIBER final)** 
n 24,927 80,425 32,756 
Patient factors    
Male 63% 60% 61% 
Age, years 65 (58, 72) 69 (62, 74) 70 (62, 75) 
European 63% 82% 97% 
NZ Māori 17% Not available Not available 
Pacific 10% Not available Not available 
Indian 6% 2% 3% 
East Asian 4% 0.1% 0.1% 
Family history of prem. CVD 21% Not available 0% 
Medical history    
Prior MI or stroke 47% 24% 25% 
Heart failure 20% 18% 20% 
Diabetes 36% 24% 29% 
Current smoker 15% 23% 22% 
Clinical factors    
Body mass index, kg/m2 29 (26, 33) 28 (25, 33) 29 (25, 33) 
Systolic BP, mmHg 130 (121, 141) 139 (125, 149) 139 (126, 150) 
Laboratory values    
TC:HDL 3.6 (3.0, 4.4) 3.5 (2.9, 4.3) 3.5 (2.9, 4.3) 
Glucose, mmol/L 5.7 (5.1, 7.2) 5.8 (5.0, 8.1) 5.8 (5.0, 8.1) 
Creatinine, μmol/L 85 (73, 99) 94 (82, 109) 94 (81, 109) 
Urate, mmol/L 0.36 (0.30, 0.43) 0.35 (0.28, 0.43) 0.35 (0.29, 0.43) 
White cell count, mmol/L 7.1 (6.0, 8.7) 7.1 (6.0, 8.6) 7.1 (5.9, 8.7) 
Haemoglobin, g/L 141 (129, 150) 140 (131, 150) 138 (128, 149) 
Medications    
BP lowering 82% 84% 91% 
Statin 75% 78% 87% 
Warfarin 9% 13% 14% 
By 2 years     
CV events 5.9% 5.7% 4.7% 
*After exclusions for inconsistent dates or measurements outside the nominal start date of 1 January 
2006;**Only includes ethnic groups included in the NZ equations. Family history of premature CVD 
was not available in the UK data so this was set to ‘none’ for all subjects.  
 
 
